Wafergen Prices Public Offering; Anticipates up to $20.8M in Net Proceeds | GenomeWeb

NEW YORK (GenomeWeb) – Wafergen Biosystems priced its public offering of Class A units, saying it anticipates net proceeds of up to $20.8 million. 

In an amended Form S-1 filed with the US Securities and Exchange Commission on Wednesday, the firm said that plans to offer 2,000 Class A units, with each unit comprising 3,077 shares of Wafergen's common stock and 1,538 warrants to purchase shares of its common stock, together with the shares of common stock underlying such warrants. Each unit is priced at $10,000. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.